Victoria Whyte Sells 5,199 Shares of GlaxoSmithKline plc (GSK) Stock

GlaxoSmithKline plc (LON:GSK) insider Victoria Whyte sold 5,199 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of GBX 1,295 ($17.89), for a total transaction of £67,327.05 ($93,018.86).

GlaxoSmithKline plc (LON GSK) opened at GBX 1,291 ($17.84) on Wednesday. The firm has a market cap of $64,010.00 and a PE ratio of 4,164.52. GlaxoSmithKline plc has a 1 year low of GBX 1,235.20 ($17.07) and a 1 year high of GBX 1,724.50 ($23.83).

The business also recently declared a dividend, which will be paid on Thursday, April 12th. Investors of record on Thursday, February 22nd will be given a dividend of GBX 23 ($0.32) per share. The ex-dividend date of this dividend is Thursday, February 22nd. This represents a yield of 1.78%. This is a positive change from GlaxoSmithKline’s previous dividend of $19.00.

GSK has been the subject of a number of recent research reports. Societe Generale restated a “sell” rating on shares of GlaxoSmithKline in a research note on Thursday, November 9th. Berenberg Bank decreased their price target on shares of GlaxoSmithKline from GBX 1,835 ($25.35) to GBX 1,760 ($24.32) and set a “buy” rating for the company in a research note on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($20.03) price target on shares of GlaxoSmithKline and gave the company a “sell” rating in a research note on Monday, November 6th. Deutsche Bank set a GBX 1,610 ($22.24) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Friday, October 27th. Finally, Barclays restated an “equal weight” rating and set a GBX 1,450 ($20.03) price target on shares of GlaxoSmithKline in a research note on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus price target of GBX 1,540.45 ($21.28).

COPYRIGHT VIOLATION WARNING: “Victoria Whyte Sells 5,199 Shares of GlaxoSmithKline plc (GSK) Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/14/victoria-whyte-sells-5199-shares-of-glaxosmithkline-plc-gsk-stock.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply